By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Sangamo Therapeutics (Formerly Known As Sangamo BioSciences, Inc.) 

501 Canal Boulevard
Suite A100
Richmond  California  94804  U.S.A.
Phone: 510-970-6000 Fax: 510-236-8951


SEARCH JOBS


Key Statistics


Email: lanphier@sangamo.com
Ownership: Public

Web Site: Sangamo
Employees:
Symbol: SGMO
 



Industry
Biotechnology






Company News
Sangamo (SGMO) Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II 7/14/2017 6:30:45 AM
Sangamo (SGMO) Appoints Roger Jeffs, Ph.D. And Joseph S. Zakrzewski To Its Board Of Directors 6/30/2017 8:43:40 AM
Sangamo (SGMO) Announces Closing Of Public Offering Of Common Stock And Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock 6/27/2017 9:07:44 AM
Sangamo (SGMO) Announces Pricing Of $72.5 Million Public Offering Of Common Stock 6/21/2017 8:38:36 AM
Sangamo (SGMO) Announces Proposed Public Offering Of Common Stock 6/21/2017 7:28:04 AM
Sangamo (SGMO) And Pfizer (PFE) Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The EMA 6/7/2017 7:26:12 AM
Sangamo (SGMO) Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy 5/16/2017 9:12:39 AM
Sangamo (SGMO) Presents Recent Developments From Research And Clinical Programs At Annual Meeting Of The American Society Of Gene & Cell Therapy 5/15/2017 9:42:56 AM
Sangamo (SGMO) Reports First Quarter 2017 Financial Results 5/11/2017 8:38:08 AM
Pfizer (PFE) Makes a $545 Million Deal With Another Bay Area Biotech, Sangamo (SGMO) 5/11/2017 5:45:19 AM
12345678910...
//-->